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1. INTRODUCTION {#dad212029-sec-0060}
===============

Amyloid β (Aβ) aggregation in the brain is the pathological hallmark of Alzheimer\'s disease (AD).[^1^](#dad212029-bib-0001){ref-type="ref"}, [^2^](#dad212029-bib-0002){ref-type="ref"}, [^3^](#dad212029-bib-0003){ref-type="ref"}, [^4^](#dad212029-bib-0004){ref-type="ref"} Toxic effects of these Aβ aggregates are correlated with the predominance of N‐terminally truncated species over the full‐length Aβ.[^5^](#dad212029-bib-0005){ref-type="ref"}, [^6^](#dad212029-bib-0006){ref-type="ref"}, [^7^](#dad212029-bib-0007){ref-type="ref"} Using mass spectrometry, various types of N‐terminally truncated species of Aβ~n‐40/42~ are found in AD brain tissue, including N‐terminally truncated Aβ~3‐40/42~ that have been further catalyzed by glutaminyl cyclase to form pyroglutamate Aβ cyclization (Aβ~pE3~) variants.[^8^](#dad212029-bib-0008){ref-type="ref"}, [^9^](#dad212029-bib-0009){ref-type="ref"}, [^10^](#dad212029-bib-0010){ref-type="ref"} The particular Aβ form has high toxicity, high resistance to proteolytic degradation, increased hydrophobicity, and faster aggregation.[^7^](#dad212029-bib-0007){ref-type="ref"}, [^11^](#dad212029-bib-0011){ref-type="ref"}, [^12^](#dad212029-bib-0012){ref-type="ref"}, [^13^](#dad212029-bib-0013){ref-type="ref"} Thus, Aβ~pE3~ may be an important culprit during AD initiation and progression.

Aβ~pE3~ is evidenced as a major constituent of intra‐/extracellular and vascular Aβ deposits in AD brain tissue.[^14^](#dad212029-bib-0014){ref-type="ref"}, [^15^](#dad212029-bib-0015){ref-type="ref"}, [^16^](#dad212029-bib-0016){ref-type="ref"} In addition to *post mortem* human brain tissues, the abnormal levels of Aβ~pE3~ in the brain and the co‐localization of Aβ~pE3~ with Aβ plaques were found in different animal models, such as transgenic mice, canines, and Caribbean vervets.[^17^](#dad212029-bib-0017){ref-type="ref"}, [^18^](#dad212029-bib-0018){ref-type="ref"}, [^19^](#dad212029-bib-0019){ref-type="ref"} These results suggest that Aβ~pE3~ is a potential seeding species and may play an important role in the formation of pathological Aβ aggregates in the brain.[^14^](#dad212029-bib-0014){ref-type="ref"}, [^20^](#dad212029-bib-0020){ref-type="ref"} It could also be a biomarker specific for Aβ plaque pathology in the brain.[^21^](#dad212029-bib-0021){ref-type="ref"}

So far, the reported evidence for finding abnormal amyloidosis by Aβ~pE3~ in AD is tissues of animals or *post mortem* human brains. The difficulties of obtaining human brain samples seriously limit the exploration of Aβ~pE3~ in clinical cohorts. It is believed that the measurement Aβ~pE3~ in body fluids such as plasma would be important to further explore the relevance of Aβ~pE3~ in AD pathogenesis, and plasma Aβ~pE3~ may also have a potential as a diagnostic tool in the clinic. However, the concentration of Aβ~pE3~ in human body fluid is extremely low. An ultra‐high‐sensitive assay technology is needed for detecting Aβ~pE3~ in human body fluids.

Immunomagnetic reduction (IMR) is an ultra‐sensitive technology for assaying biomarkers at pg/mL or lower.[^22^](#dad212029-bib-0022){ref-type="ref"}, [^23^](#dad212029-bib-0023){ref-type="ref"} In addition, the correlation between these plasmas biomarkers and their concentration in cerebrospinal fluid (CSF),[^24^](#dad212029-bib-0024){ref-type="ref"} and their relation to neuroimaging measures such as Aβ positron emission tomography (PET) have been clarified.[^25^](#dad212029-bib-0025){ref-type="ref"}, [^26^](#dad212029-bib-0026){ref-type="ref"} The results reveal the reliabilities of assaying ultra‐low‐concentrated biomarkers using IMR. In this work, IMR was used to develop the quantitative detection of Aβ~pE3‐40~ in human plasma. Moreover, 28 subjects with negative Aβ PET (PET‐) and 18 subjects with positive Aβ PET (PET+) were enrolled. The measured concentrations of plasma Aβ~pE3‐40~ of these subjects were compared with amyloid PET. Moreover, the plasma Aβ~1‐40~ of all subjects were assayed using an IMR Aβ~1‐40~ kit to explore the roles of Aβ~1‐40~ and Aβ~pE3‐40~ in discriminating Aβ PET status.

Research in Context {#dad212029-sec-0070}
-------------------

Pyroglutamate‐modified amyloid β (Aβ~pE3~) is a modified Aβ peptide that co‐oligomerizes with Aβ~42~ and deposited in the Alzheimer\'s disease (AD) brain. Aβ~pE3~ may act as a seed for misfolding of Aβ at a primary step in AD. The concentration of Aβ~pE3~ in body fluid is extremely low. Therefore, an ultra‐sensitive assay such as immunomagnetic reduction assay is developed to detect the level of Aβ~pE3~ in plasma.We developed a new analysis method to measure the concentration of Aβ~pE3~. This study demonstrates the plasma Aβ~pE3‐40~ showed a correlation with Aβ positron emission tomography (PET) status and standardized uptake value ratio, which may be of value for screening and diagnosis as well as for applications in longitudinal clinical research studies and to monitor treatments in clinical trials.Detection of plasma Aβ~pE3‐40~ in early stages could be a potential strategy for early diagnosis of AD. However, more participants should be enrolled for validating the correlation between Aβ~pE3‐40~ and Aβ PET status.

2. METHODS {#dad212029-sec-0080}
==========

2.1. IMR reagent for assaying Aβ~pE3‐40~ {#dad212029-sec-0090}
----------------------------------------

Antibodies against Aβ~pE3‐40~ were developed by Biogen Inc. According to the results via direct binding enzyme‐linked immunosorbent assay (ELISA), the antibodies show strong reactivity to Aβ~pE3‐40~ and Aβ~3‐40~ (\>0.3 nM), and weak reactivity to Aβ~1‐40~, but not Aβ~pE11‐40~. There is not any available data concerning the reactivity with Aβ~pE3‐42~. Antibodies against Aβ~pE3‐40~ were covalently bound to dextran‐coated Fe~3~O~4~ nanoparticles (MF‐DEX‐0060, MagQu) via the chemical reactions in Yang et al.^27^

2.2. IMR measurements {#dad212029-sec-0100}
---------------------

The IMR analyzer (XacPro‐S, MagQu) was used to detect the reduction in the magnetic signals of reagent due to the association between antibody‐functionalized magnetic nanoparticles and Aβ~pE3‐40~ molecules. The ratio of the reduction to the alternative‐current magnetic signal of reagent before incubation is referred as IMR signal, as expressed$${{IMR}\mspace{6mu}}\left( \% \right) = \frac{\chi_{ac,o} - \chi_{ac,\phi}}{\chi_{ac,o}}\mspace{6mu} x100\%,$$where *χ* ~ac,o~ and *χ* ~ac,ϕ~ are the alternative‐current magnetic signals of reagent before and after incubation. For each reported IMR (%) in this work, an averaged value of duplicated IMR measurements was used.

2.3. Recruitment of subjects {#dad212029-sec-0110}
----------------------------

All subjects were recruited in the study of the Alzheimer\'s Disease Neuroimaging Initiative at Taipei Veterans General Hospital (Taipei VGH), Linkou Chang Gung Memorial Hospital (CGMH), and Kaohsiung CGMH in Taiwan (T‐ADNI). The T‐ADNI study was approved by the ethics committees of the three hospitals. All participants were asked to complete written informed consents for this study.

Enrolled subjects were required to be aged \>55 years. Magnetic resonance imaging (MRI) was used to exclude subjects with major neuropathologies such as tumors, strokes, severe white matter disease, or inflammation, but MRI was not used to diagnose dementia. Subjects with history of major brain trauma, stroke, brain tumor, epilepsy, major psychiatric illness, alcoholism, or other systemic diseases that might affect cognitive function were ruled out in this study.

The study included a battery of neuropsychological tests including the Geriatric Depression Scale, a Mini‐Mental State Examination (MMSE), and the Chinese version of the Wechsler Memory Scale‐III (WMS‐III). A Clinical Dementia Rating Scale (CDR) score was performed for each enrolled subject. Patients with AD and amnestic mild cognitive impairment (aMCI) patients follows criteria of National Institute on Aging and the Alzheimer\'s Association (NIA‐AA).[^28^](#dad212029-bib-0028){ref-type="ref"}

2.4. Collection and preparation of human plasma samples {#dad212029-sec-0120}
-------------------------------------------------------

Each enrolled subject provided a 9 mL non‐fasting venous blood sample (K3 ethylenediaminetetraacetic acid \[EDTA\], lavender‐top tube). Blood samples were centrifuged at 1500 to 2500 × g at room temperature for 15 minutes within 1 hour after blood draw. Plasma was then aliquoted into cryotubes (0.5 mL aliquots) and stored at ‐20°C.

2.5. Analysis of apolipoprotein E (APOE)genotypes {#dad212029-sec-0130}
-------------------------------------------------

*APOE* genotyping was performed for each enrolled subject by polymerase chain reaction (PCR) amplification of a 500 base‐pair fragment of the *APOE* gene spanning the bases coding for amino acid positions 112 and 158, followed by direct DNA sequencing.[^29^](#dad212029-bib-0029){ref-type="ref"} Subjects with either one or two ε4 alleles were regarded as ε4 carriers.

2.6. Aβ PET imaging {#dad212029-sec-0140}
-------------------

All PET images were acquired from Linkou Chang Gung Memorial Hospital. The details of Aβ PET imaging were described in Lin et al. and Hsiao [et al](#dad212029-bib-0031){ref-type="ref"}.[^30^](#dad212029-bib-0030){ref-type="ref"}, [^31^](#dad212029-bib-0031){ref-type="ref"} The ^18^F‐florbetapir PET scan comprised a 10‐minute acquisition period (acquired in 2 × 5minute frames) beginning 50 minutes following 10 mCi injection of the 18F‐florbetapir tracer. Imaging was performed on a Biograph mCT PET/CT scanner (GE Healthcare, Milwaukee, WI, USA). Structural MRI scans were acquired using a uniform scanning protocol that minimized and accounted for between‐site differences in MRI systems.

All PET image data were processed and analyzed using PMOD image analysis software (version 3.7, PMOD Technologies Ltd., Zurich, Switzerland), including MR‐based spatial normalization to the Montreal Neurological Institute (MNI) MRI template. Seven volumes of interest (VOIs), the frontal, anterior cingulate, posterior cingulate, precuneus, parietal, occipital, and temporal areas, were selected, and the regional standardized uptake value ratio (SUVR) using the whole cerebellum as the reference region was calculated for each VOI. Moreover, the average SUVR from these seven cerebral cortical VOIs was computed to yield an estimate of global cortical SUVR for further analysis.

The PET images were interpreted blindly by an experienced nuclear medicine physician (Kun‐Ju Lin). A five‐point visual scale was used to classify the amyloid loading, from 0, indicated no tracer retention in cortical gray matter, to 4, indicated high levels of cortical amyloid accumulation. Visual rating scores of 2 to 4 were considered indicative of amyloid PET+ brains and ratings of 0 to 1 were considered negative for amyloid PET.[^32^](#dad212029-bib-0032){ref-type="ref"}

2.7. Assay of plasma Aβ~1‐40~ {#dad212029-sec-0150}
-----------------------------

IMR reagent for Aβ~1‐40~ (MF‐AB0‐0060, MagQu) with an aid of IMR analyzer (XacPro‐S, MagQu) were used to detect the concentrations of plasma Aβ~1‐40~ of subjects. Duplicated measurements were done for each sample. The reported concentration of the plasma Aβ~1‐40~ is the mean value of the duplicated measurements. The variations of measured concentrations of control solutions with respect to the known concentrations should be \<15%.

2.8. Statistical methods {#dad212029-sec-0160}
------------------------

Continuous variables for each measurement are presented as means ± standard deviations. Continuous variables were compared using a *t*‐test, and *P*‐values were determined. Pearson correlation r was done with GraphPad Prism. Negative, positive, overall percentage agreements were calculated to quantify the consistency between plasma‐biomarker diagnosis and clinical diagnosis.

3. RESULTS {#dad212029-sec-0170}
==========

3.1. Aβ~pE3‐40~ concentration‐dependent IMR(%) {#dad212029-sec-0180}
----------------------------------------------

Phosphate buffered saline (PBS) solutions spiked with various concentrations of Aβ~pE3‐40~ from 0.1 fg/mL to 1000 pg/mL were assayed with IMR. For each concentration, duplicated IMR measurements were performed. The averaged IMR(%) of the duplicated measurement was used to establish the relationship between IMR(%) and Aβ~pE3‐40~ concentration. Figure [1A](#dad212029-fig-0001){ref-type="fig"} shows the relationship between IMR(%) and spiked Aβ~pE3‐40~ concentration. The error bars with each data point are attributed from the duplicated measurements. It was observed in Figure [1A](#dad212029-fig-0001){ref-type="fig"} that IMR(%) increased from 2.69% to 4.42% as spiked β~pE3‐40~ concentration increases from 0.1 fg/mL to 1000 pg/mL. The relationship in Figure [1A](#dad212029-fig-0001){ref-type="fig"} follows the logistic function$${{IMR}\mspace{6mu}}\left( \% \right) = \left\lbrack {\frac{A - B}{1 + \left( \frac{\phi_{A\beta_{pE3 - 40}}}{\phi_{o}} \right)^{\gamma}} + B} \right\rbrack{\mspace{6mu}\%},$$where *A*, *B*, *ϕ* ~o~, and *γ* are fitting parameters; *ϕ* ~AβpE3‐40~ denotes the spiked Aβ~pE3‐40~ concentration in PBS. By fitting Equation ([2](#dad212029-disp-0002){ref-type="disp-formula"}) to the experimental data points in Figure [1A](#dad212029-fig-0001){ref-type="fig"}, the values for the parameters *A*, *B*, *ϕ* ~o~, and *γ* were found to be 2.69, 4.46, 1.67, and 0.628, respectively. *A* in Equation. ([2](#dad212029-disp-0002){ref-type="disp-formula"}) is the IMR(%) as the spiked Aβ~pE3‐40~ concentration approaches zero. Thus, *A* denotes the noise level for IMR(%). *B* in Equation. ([2](#dad212029-disp-0002){ref-type="disp-formula"}) is the IMR(%) as the spiked Aβ~pE3‐40~ concentration approaches infinity. Thus, *B* denotes the upper‐limit signal for IMR(%).

![A, Amyloid β (Aβ~pE3‐40~) concentration‐dependent IMR signals and (B) relationship between spiked concentration of Aβ~pE3‐40~ (*x* axis) and measured concentration of Aβ~pE3‐40~ (*y* axis) using immunomagnetic reduction](DAD2-12-e12029-g001){#dad212029-fig-0001}

3.2. Lower limit of detection of the Aβ~pE3‐40~ assay {#dad212029-sec-0190}
-----------------------------------------------------

The lower limit of detection is usually defined as the concentration showing the IMR(%) higher than the noise level by triple standard deviation for IMR signals at low concentrations. According to the results in Table [1](#dad212029-tbl-0001){ref-type="table"}, the standard deviation for IMR(%) at low concentrations, such as the spiked 0.001‐pg/mL Aβ~pE3‐40~, was found to be 0.06%. Thus, the lower limit of detection in terms of IMR(%) was (2.69 + 3 × 0.06)% = 2.88%. Via the logistic function in Equation ([2](#dad212029-disp-0002){ref-type="disp-formula"}), the lower limit of detection for assaying Aβ~pE3‐40~ using IMR was around 0.005 pg/mL, that is, 5 fg/mL.

###### 

Interference tests of Aβ~3‐40~, Aβ~1‐42~, and Aβ~1‐40~ for assaying Aβ~pE3‐40~ using immunomagnetic reduction

                                                                Measured Aβ pE3‐40 concentration                    
  --- --------------------------------------------------------- ---------------------------------- -------- ------- --------
  1   Plasma                                                    0.0229                             0.0061   26.46   ‐
  2   Plasma + Aβ~pE3‐40~ (0.05 pg/mL)                          0.0741                             0.0051   6.83    (Ref.)
  3   Plasma + Aβ~pE3‐40~ (0.05 pg/mL) +Aβ~3‐40~ (20 pg/mL)     0.0781                             0.0105   13.47   105.46
  4   Plasma + Aβ~pE3‐40~ (0.05 pg/mL) +Aβ~1‐42~ (20 pg/mL)     0.0734                             0.0064   8.72    99.06
  5   Plasma + Aβ~pE3‐40~ (0.05 pg/mL) + Aβ~1‐40~ (80 pg/mL)    0.0776                             0.0089   11.45   104.73
  6   Plasma + Aβ~pE3‐40~ (0.05 pg/mL) + Aβ~1‐40~ (100 pg/mL)   0.0842                             0.0023   2.76    113.66

Abbreviations: Aβ, amyloid β; CV, coefficient of variation; SD, standard deviation

John Wiley & Sons, Ltd.

3.3. Measurement range of the Aβ~pE3‐40~ assay {#dad212029-sec-0200}
----------------------------------------------

The measured IMR(%) in Figure [1A](#dad212029-fig-0001){ref-type="fig"} was converted to the measured Aβ~pE3‐40~ concentration via Equation ([2](#dad212029-disp-0002){ref-type="disp-formula"}). The correlations between measured Aβ~pE3‐40~ concentrations and spiked Aβ~pE3‐40~ concentrations were investigated. The results are shown in Figure [1B](#dad212029-fig-0001){ref-type="fig"}. Notably, one of the duplicated measurements of IMR(%) for 0.1 fg/mL Aβ~pE3‐40~ PBS sample was \<2.69%, which was the noise level of IMR(%). The measured Aβ~pE3‐40~ concentration was not available for this IMR(%) \<2.69%. Hence, the measured Aβ~pE3‐40~ concentration for the spiked 0.1 fg/mL Aβ~pE3‐40~ PBS sample was not counted in Figure [1B](#dad212029-fig-0001){ref-type="fig"}. Meanwhile, one of duplicated measurements of IMR(%) for 1000‐pg/mL Aβ~pE3‐40~ PBS sample was \> 4.46%, which was the upper‐limit signal of IMR(%). The measured Aβ~pE3‐40~ concentration was not available for this IMR(%) \>4.46%. Hence, the measured Aβ~pE3‐40~ concentration for the spiked 1000‐pg/mL Aβ~pE3‐40~ PBS sample was not counted in Figure [1B](#dad212029-fig-0001){ref-type="fig"} either. The measured Aβ~pE3‐40~ concentrations versus the spiked Aβ~pE3‐40~ concentrations from 1 fg/mL to 100 pg/mL was plotted in Figure [1B](#dad212029-fig-0001){ref-type="fig"}. The slope of the linearity in Figure [1B](#dad212029-fig-0001){ref-type="fig"} was found to be 1.07. According to the Clinical & Laboratory Standards Institute (CLSI) guideline EP06‐A2, the acceptable range of the slope is from 0.9 to 1.1 for demonstrating the linearity between the measured concentrations and spiked concentrations. Therefore, by taking the results in Figures [1A](#dad212029-fig-0001){ref-type="fig"} and [1B](#dad212029-fig-0001){ref-type="fig"} into account, the measurement range of Aβ~pE3‐40~ using IMR was from 5 fg/mL to 100 pg/mL.

3.4. Interference tests of assaying Aβ~pE3‐40~ {#dad212029-sec-0210}
----------------------------------------------

Six human plasma samples were prepared for the interference tests, as tabulated in Table [1](#dad212029-tbl-0001){ref-type="table"}. Sample No. 1 was native human plasma. Sample No. 2 contained spiked Aβ~pE3‐40~ of 0.05 pg/mL. In addition to 0.05 pg/mL Aβ~pE3‐40~, Sample No. 3‐6 contained difference spiked Aβ~3‐40~ (AS‐61029, Anaspec), Aβ~1‐42~ (A9810, Sigma), or Aβ~1‐40~ (A1075, Sigma). It has been reported that the concentration of plasma Aβ~1‐42~ is around 10∼20 pg/mL, while plasma Aβ~1‐40~ is 30 to 60 pg/mL.[^24^](#dad212029-bib-0024){ref-type="ref"}, [^25^](#dad212029-bib-0025){ref-type="ref"}, [^33^](#dad212029-bib-0033){ref-type="ref"}, [^34^](#dad212029-bib-0034){ref-type="ref"} The spiked Aβ~1‐42~ and Aβ~1‐40~ concentrations in Samples No. 4 through 6 were thus reasonable. The measured Aβ~pE3‐40~ concentrations for each sample are listed in Table [1](#dad212029-tbl-0001){ref-type="table"}. The measured Aβ~pE3‐40~ concentration of Sample No. 2 was used as a reference. The recovery rates in the measured Aβ~pE3‐40~ concentrations for Samples No. 3 through 6 were calculated as the ratio of mean concentrations of duplicated measurements for each sample to that of Sample No. 2. The results are shown in Table [1](#dad212029-tbl-0001){ref-type="table"}. It was found that the recovery rates for Samples No. 3 through 5 were within the range from 90% to 110%, which means that there was no significant interference to the assay of Aβ~pE3‐40~ in Samples No. 3 through 5. However, the recovery rate of Sample No. 6 was \> 110%, which revealed that the 100‐pg/mL Aβ~1‐40~ contributed significantly to false signal for assaying Aβ~pE3‐40~ in human plasma. Fortunately, the measured Aβ~1‐40~ concentrations in human plasma were \< 100 pg/mL in both healthy controls and AD patients, that is, 30 to 60 pg/mL.[^33^](#dad212029-bib-0033){ref-type="ref"}, [^34^](#dad212029-bib-0034){ref-type="ref"} Hence, for real human plasma, there would be no significant interferences by Aβ~3‐40~, Aβ~1‐42~, or Aβ~1‐40~ to the assay of Aβ~pE3‐40~ using Aβ~pE3‐40~ IMR reagent.

3.5. Demographic characteristics of enrolled subjects {#dad212029-sec-0220}
-----------------------------------------------------

Forty‐six human plasma samples from Taiwan Alzheimer\'s Disease Neuroimaging Initiative (T‐ADNI) were assayed with Aβ~pE3‐40~ IMR reagent. The demographic characteristics, including sex, age, education, *APOE* ε4 status, CDR, MMSE, global SUVR, and measured plasma Aβ~pE3‐40~ and Aβ~1‐40~ concentrations, are shown in Table [2](#dad212029-tbl-0002){ref-type="table"}. In Table [2](#dad212029-tbl-0002){ref-type="table"}, the demographic characteristics of various diagnostic groups, that is, normal controls (NC), aMCI, and AD, in Aβ PET‐ and Aβ PET+ are also listed. The combined includes NC, aMCI, and AD. The typical Aβ PET images of enrolled subjects are shown in Figure [2](#dad212029-fig-0002){ref-type="fig"}. Figures [2A](#dad212029-fig-0002){ref-type="fig"}--[2C](#dad212029-fig-0002){ref-type="fig"} are for Aβ PET‐ and Figures [2D](#dad212029-fig-0002){ref-type="fig"} and [2E](#dad212029-fig-0002){ref-type="fig"} are for Aβ PET+.

###### 

Demographic information of enrolled subjects

  Amyloid PET                           Negative (Aβ PET‐)   Positive (Aβ PET+)                                                                               
  ------------------------------------- -------------------- -------------------- ------------------ ------------------ ------------------ ------------------ ---------------------------------------------------------------
  Female/male                           3/2                  7/11                 1/4                11/17              7/0                4/7                11/7
  Age (years)                           60.4 ± 2.8           71.2 ± 9.8           75.6 ± 11.5        70.1 ± 10.3        72.7 ± 5.9         71.2 ± 9.2         71.8 ± 7.92
  Education (years)                     14.2 ± 2.9           10.8 ± 3.6           13.0 ± 3.0         11.8 ± 3.6         12.7 ± 5.6         13.5 ± 3.1         13.2 ± 4.1
  ApoEε4 allele frequency               30%                  2.78%                0%                 7.69%              7.14%              36.36%             25%
  CDR                                   0                    0.5                  0.6 ± 0.2          0.43 ± 0.22        0.5                0.5                0.50 ± 0.00
  MMSE                                  29.6 ± 0.89          27.28 ± 2.03         24.0 ± 3.54        27.11 ± 2.74       26.14 ± 2.41       22.82 ± 2.04       24.11 ± 2.70[a](#dad212029-tbl2-note-0002){ref-type="fn"}
  Global SUVR                           1.08 ± 0.06          1.05 ± 0.20          1.11 ± 0.15        1.06 ± 0.17        1.57 ± 0.18        1.50 ± 0.17        1.53 ± 0.17[a](#dad212029-tbl2-note-0002){ref-type="fn"}
  Plasma Aβ~pE3‐40~ (fg/mL)             31.00 ± 16.88        44.59 ± 30.28        55.41 ± 28.4       44.09 ± 28.19      65.64 ± 18.56      108.2 ± 63.9       91.62 ± 54.60[a](#dad212029-tbl2-note-0002){ref-type="fn"}
  Plasma Aβ~1‐40~ (pg/mL)               44.65 ± 9.64         49.39 ± 7.18         49.53 ± 8.15       48.57 ± 7.71       54.28 ± 6.17       50.28 ± 6.91       51.84 ± 6.75
  Plasma Aβ~pE3‐40~‐to‐Aβ~1‐40~ ratio   (0.072 ± 0.048)%     (0.092 ± 0.063)%     (0.108 ± 0.041)%   (0.091 ± 0.057)%   (0.122 ± 0.040)%   (0.215 ± 0.122)%   (0.179 ± 0.107)%[a](#dad212029-tbl2-note-0002){ref-type="fn"}

Abbreviations: Aβ, amyloid β; AD, Alzheimer\'s disease; aMCI, amnestic mild cognitive impairment; CDR, clinical dementia ranking; Dx, clinical diagnosis; MMSE, mini‐mental state examination; NC, normal controls; PET, positron emission tomography; SUVR, standardized uptake value ratio.

^\*^ *P* \< .05 between Aβ PET‐ and Aβ PET+ ^\*\*^: *P* \< .001 between Aβ PET‐ and Aβ PET+

John Wiley & Sons, Ltd.

![Typical amyloid β (Aβ) positron emission tomography (PET) images of the enrolled subjects with (A) normal controls (NC) and Aβ PET‐, (B) amnestic mild cognitive impairment (aMCI) and Aβ PET‐, (C) Alzheimer\'s disease (AD) and Aβ PET‐, (D) aMCI and Aβ PET+, and (E) AD and Aβ PET+](DAD2-12-e12029-g002){#dad212029-fig-0002}

The comparisons in the demographic characteristics between Aβ PET‐ and Aβ PET+ individuals, that is, demographic characteristics in combined columns, were made. The age, education years, and CDR between Aβ PET‐ and Aβ PET+ individuals were matched. There was no significant difference in CDR between Aβ PET‐ and Aβ PET+ individuals. The frequency of *APOE* ε4 allele is much higher in Aβ PET+ (25%) as compared to Aβ PET‐ (7.69%) individuals. Meanwhile, significantly higher scores of MMSE (*P* \< .001), higher values of global SUVR (*P* \< .001), and higher levels of measured plasma Aβ~pE3‐40~ (*P* \< .05) were found in Aβ PET+ individuals. As to plasma Aβ~1‐40~ concentrations, there is no significant difference between Aβ PET‐ and Aβ PET+ individuals.

3.6. Plasma Aβ~pE3‐40~ for discriminating Aβ PET status {#dad212029-sec-0230}
-------------------------------------------------------

The measured plasma Aβ~pE3‐40~ concentrations in Aβ PET‐ and in Aβ PET+ individuals are plotted in Figure [3A](#dad212029-fig-0003){ref-type="fig"}. The error bar of each data point in Figure [3A](#dad212029-fig-0003){ref-type="fig"} is attributed from the duplicated measurements of plasma Aβ~pE3‐40~ concentrations. Concentrations of plasma Aβ~pE3‐40~ was 44.1 ± 28.2 fg/mL in Aβ PET‐ subjects, as compared with 91.6 ± 54.6 fg/mL in the Aβ PET+ group (*P* = .012). The analysis of the receiver operating characteristic (ROC) curve was performed for the data shown in Figure [3A](#dad212029-fig-0003){ref-type="fig"}. The ROC curve is shown Figure [3B](#dad212029-fig-0003){ref-type="fig"}. The cutoff value of plasma Aβ~pE3‐40~ concentration for discriminating Aβ PET‐ from Aβ PET+ individuals was 56.3 fg/mL, as plotted with the gray dashed line in Figure [3A](#dad212029-fig-0003){ref-type="fig"}. The corresponding clinical sensitivity and specificity was 79.0% and 71.4%, respectively. The area under the curve (AUC) was 0.808.

![(A) Measured concentrations of plasma amyloid β (Aβ~pE3‐40~) in Aβ‐positron emission tomography (PET)‐ and Aβ‐PET+ subjects using immunomagnetic reduction and (B) receiver operating characteristic (ROC) curve for differentiating PET‐ from PET+, (C) correlation between measured concentrations of plasma Aβ~pE3‐40~ and global standardized uptake value ratio](DAD2-12-e12029-g003){#dad212029-fig-0003}

3.7. Correlation between plasma Aβ~pE3‐40~ and SUVR {#dad212029-sec-0240}
---------------------------------------------------

The relationship between measured plasma Aβ~pE3‐40~ concentration and global SUVR is shown in Figure [3C](#dad212029-fig-0003){ref-type="fig"}. Through Pearson correlation analysis, the correlation coefficient r was found to be 0.450 (*P* \< .05), as guided with the gray dashed line in Figure [3C](#dad212029-fig-0003){ref-type="fig"}.

4. DISCUSSION {#dad212029-sec-0250}
=============

Although Aβ PET is approved for diagnosing AD in clinics, it is a very costly and not that accessible of an examination. It would be better to have a screening tool for evaluating the requirement of performing Aβ‐PET examination, such as a blood test. Many research groups have tried to develop methods to quantify plasma Aβ in a manner that correlates with Aβ PET. Table [3](#dad212029-tbl-0003){ref-type="table"} lists some typical results showing the possibilities to discriminate Aβ PET‐ from PET+ using human plasma Aβ species, with Aβ~1‐40~ and Aβ~1‐42~ being the core biomarkers in these studies. Depending on the clinical diagnosis of enrolled subjects, assay methods and plasma biomarkers, the AUC of discriminating Aβ PET‐ and PET+ ranges from 0.66 to 0.969. However, studies on the role of plasma Aβ~pE3‐40~ in differentiating Aβ PET status are currently lacking. To our knowledge, this is the first study to report the feasibility of discriminating Aβ PET‐ and PET+ by using plasma Aβ~pE3‐40~ in humans. The AUC of 0.808 suggests that Aβ~pE3‐40~ in plasma is a promising test for detecting Aβ PET+, which may be of value for screening and diagnosis as well as for applications in longitudinal clinical research studies and to monitor treatments in clinical trials.

###### 

Reported plasma Aβ biomarkers for differentiating Aβ PET‐ from PET+ in AD

                                                                                                             Aβ PET‐ vs. Aβ PET+   *P*                     
  --------------------------------------------- --------------- ----- ---------------- --------------------- --------------------- ------- ------- ------- ---------
  [^37^](#dad212029-bib-0037){ref-type="ref"}   NC              76    Sandwich ELISA   Aβ~1‐42~/Aβ~1‐40~     ---                   71%     78%     0.79    ‐
  [^38^](#dad212029-bib-0038){ref-type="ref"}   ^SCD^           200   Sandwich ELISA   Aβ~1‐42~/Aβ~1‐40~     0.08                  83.3%   51.9%   0.68    −
  [^39^](#dad212029-bib-0039){ref-type="ref"}   ^NC\ +\ MCI^    39    Sandwich ELISA   Aβ~1‐40~              ---                   −       −       −       .04
                                                                                       Aβ~1‐42~/Aβ~1‐40~     ---                   −       −       −       .02
  ^40^                                          ^SCD^           69    SIMOA            Aβ~1‐40~              ---                   −       −       0.66    .018
                                                                                       Aβ~1‐42~/Aβ~1‐40~     ---                   70%     78%     0.79    −
  ^41^                                          NC + MCI +AD    66    IP‐MS            Aβ~1‐42~              0.183 pg/mL           0.825   0.773   0.808   −
                                                                                       Aβ~1‐42~/Aβ~1‐40~     0.009                 0.750   0.773   0.798   −
                                                                                       APP669‐711/Aβ~1‐42~   0.914                 0.925   0.955   0.969   −
  [^30^](#dad212029-bib-0030){ref-type="ref"}   NC + MCI +AD    45    IMR              Aβ~1‐42~/Aβ~1‐40~     −                     −       −       −       \< .001
  This work                                     NC + aMCI +AD   46    IMR              Aβ~pE3‐40~            55.45 fg/mL           83.3%   71.4%   0.808   .0012

Abbreviations: Aβ, amyloid β; AD, Alzheimer\'s disease; aMCI, amnestic mild cognitive impairment; AUC, area under curve; ELISA, enzyme‐linked immunosorbent assay; IMR, immunomagnetic reduction; IP‐MS, immunoprecipitation mass spectrometry; MCI, mild cognitive impairment impairment; NC, normal controls; PET, positron emission tomography; SCD, subjective cognition decline; SIMOA, single molecule array
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The dependence of plasma Aβ~pE3‐40~ on *APOE* ε4 genotype was investigated. There was no significant difference (*P* \> .05) in the levels of plasma Aβ~pE3‐40~ between *APOE* ε4 non‐carriers (56.58 ± 44.24 fg/mL) and carriers (80.00 ± 49.92 fg/mL), which resonates well with the fact that Aβ~pE3‐40~ is generated from Aβ~1‐40~ via truncation and pyroglutamation; a process not directly related to *APOE* genotype. There was no significant difference in levels of plasma Aβ~1‐40~ between Aβ PET‐ and PET+ individuals, but the levels of plasma Aβ~pE3‐40~ in Aβ PET+ subjects were higher, suggesting that Aβ~pE3‐40~ is more crucial than Aβ~1‐40~ to the formation of Aβ plaques in the brain. The result is corroborated by the plasma Aβ~pE3‐40~‐to‐Aβ~1‐40~ ratio, which was significantly higher (*P* \< .05) in Aβ PET+ (0.179% ± 0.107%) as compared to Aβ PET‐ individuals (0.091% ± 0.057%).

The roles of plasma Aβ~pE3‐40~ in determining cognitive‐disorder severity are investigated. As listed in Table [2](#dad212029-tbl-0002){ref-type="table"}, for Aβ PET‐ individuals, MMSE significantly decreases from NC to aMCI and AD (*P* \< .001). An obviously different degree of severity in cognitive disorder among diagnostic groups was evidenced in Aβ PET‐ individuals. Although the mean value of plasma Aβ~pE3‐40~ concentrations increases from NC (31.00 fg/mL), aMCI (44.59 fg/mL) to AD (55.41 fg/mL) for Aβ PET‐ individuals, there is no significant difference among these diagnostic groups. This might be due to the limited range for plasma Aβ~pE3‐40~ concentrations in Aβ PET‐ individuals (44.09 ± 28.19 fg/mL). However, for Aβ PET+ individuals, the plasma Aβ~pE3‐40~ concentrations distribute much more heterogeneously (91.62 ± 54.60 fg/mL) as compared to that for Aβ PET‐ individuals, as shown in Figure [3A](#dad212029-fig-0003){ref-type="fig"}. It might be possible to find the significant difference in the plasma Aβ~pE3‐40~ concentrations between aMCI and AD in Aβ PET+ individuals. As tabulated in Table [2](#dad212029-tbl-0002){ref-type="table"}, AD with Aβ PET+ shows significantly higher levels of plasma Aβ~pE3‐40~ (108.2 ± 63.9 fg/mL) than that of aMCI (65.64 ± 18.56 fg/mL, *P* \< .05) with Aβ PET+. These results reveal that plasma Aβ~pE3‐40~ level is not only promising to discriminate Aβ PET status, but also able to determine the severity of cognitive disorder in Aβ PET+ individuals.

As expected, the concentration of Aβ~pE3‐40~ in human plasma was very low. With the development of ultra‐sensitive assays like IMR, it becomes feasible to precisely detect such low concentrations of biomarkers in human plasma. More investigations in plasma Aβ~pE3‐40~ shall be explored using ultra‐sensitive assays in the future.

There are some limitations in this work. For example, the total number of enrolled subjects is relatively limited. More subjects should be enrolled for validating the cutoff value of plasma Aβ~pE3‐40~ to discriminate Aβ PET status in future studies. Moreover, we did not enroll any pre‐clinical AD subject, that is, subjects with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using plasma Aβ~pE3‐40~ for screening pre‐clinical subjects.

5. CONCLUSION {#dad212029-sec-0260}
=============

Reagent for assaying plasma Aβ~pE3‐40~ by using immunomagnetic reduction were developed. The measurement range of assaying Aβ~pE3‐40~ was 5 fg/mL to 100 pg/mL. The levels of plasma Aβ~pE3‐40~ were found to be able to discriminate Aβ PET status. The cutoff value of plasma Aβ~pE3‐40~ for discriminating PET‐ from PET+ was 55.5 fg/mL, showing the sensitivity of 83.3%, specificity of 71.4% ,and area under curve of 0.808. Moreover, plasma Aβ~pE3‐40~ level is promising to determine the severity of cognitive disorder in Aβ PET+ individuals. As compared to the native primary structure of Aβ~1‐40~, the pyroglutamate modification was more closely related to Aβ pathology in the brain. It was also found that Aβ~pE3‐40~ is independent of ApoE genotype.
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